Explore
Validate
Learn500-P38-100UG
antibody from Invitrogen Antibodies
Targeting: CCL3
G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P38-100UG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CCL3 Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: ASLAADTPTA CCFSYTSRQI PQNFIADYFE TSSQCSKPGV IFLTKRSRQV CADPSEEWVQ KYVSDLELSA. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human MIP-1alpha (CCL3). Anti-Human MIP-1alpha (CCL3)-specific antibody was purified by affinity chromatography employing an immobilized Human MIP-1alpha (CCL3) matrix. Sandwich ELISA: To detect Human MIP-1alpha (CCL3) by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human MIP-1alpha (CCL3) (500-P38Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human MIP-1alpha (CCL3). Western Blot: To detect Human MIP-1alpha by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human MIP-1alpha is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 100 µg
- Concentration
- 0.1-1.0 mg/mL
- Storage
- -20°C
Submitted references Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated receptor-gamma upregulation.
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge.
Rius C, Abu-Taha M, Hermenegildo C, Piqueras L, Cerda-Nicolas JM, Issekutz AC, Estañ L, Cortijo J, Morcillo EJ, Orallo F, Sanz MJ
Journal of immunology (Baltimore, Md. : 1950) 2010 Sep 15;185(6):3718-27
Journal of immunology (Baltimore, Md. : 1950) 2010 Sep 15;185(6):3718-27
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
Izhak L, Wildbaum G, Weinberg U, Shaked Y, Alami J, Dumont D, Friedman B, Stein A, Karin N
Journal of immunology (Baltimore, Md. : 1950) 2010 Jan 15;184(2):1092-101
Journal of immunology (Baltimore, Md. : 1950) 2010 Jan 15;184(2):1092-101
CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge.
Pilette C, Francis JN, Till SJ, Durham SR
The European respiratory journal 2004 Jun;23(6):876-84
The European respiratory journal 2004 Jun;23(6):876-84
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human MIP-1alpha (CCL3) by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of CCL3 Polyclonal Antibody (Product # 500-P38-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech CCL3 Polyclonal Antibody, Biotin (Product # 500-P38BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human MIP-1alpha (CCL3).
